Key clinical point: The progression-free survival benefit of 2 years of rituximab maintenance therapy in follicular lymphoma is durable long term.

Major finding: At a median follow-up of 9 years, progression-free survival was 10.5 years with rituximab maintenance, compared with 4.1 years with observation (hazard ratio, 0.61; P less than .001).

Study details: A final efficacy analysis of a phase 3, randomized, controlled trial involving 607 patients with follicular lymphoma who had responded to immunochemotherapy induction.

Disclosures: The trial was sponsored by the Lymphoma Study Association and supported by F. Hoffmann–La Roche and Biogen. Dr. Bachy reported financial disclosures related to Roche and other companies.